SYMBICORT® (budesonide and formoterol fumarate dihydrate) budesonide/formoterol

SYMBICORT combines an ICS, budesonide and a LABA medicine, formoterol. LABA medicines, such as formoterol, when used alone can increase the risk of hospitalizations and death from …

AstraZeneca Pharmaceuticals LP. Rennard SI, Tashkin DP, McElhattan J, et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose …

Jan 30, 2017 · This trial demonstrated budesonide/formoterol 80/4.5 micrograms delivered in a pressurised metered-dose inhaler (pMDI) significantly improved lung function in paediatric …

SYMBICORT TURBUHALER (budesonide and formoterolfumarate dihydrate) is indicated for the treatment of asthma in patients 12 years and older with reversible obstructive airways disease.

Jan 30, 2017 · AstraZeneca today announced that the US Food and Drug Administration (FDA) approved SYMBICORT ® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol …

Treatment of asthma in patients 12 years and older: 2 inhalations of SYMBICORT 80/4.5 or 160/4.5 twice daily. Starting dosage is based on asthma severity. (2.2) Metered-dose inhaler …

Sep 10, 2017 · INCONTROL 1 demonstrates a protective benefit of budesonide/formoterol compared to formoterol against exacerbation in COPD patients with blood eosinophils 0.1 x10 …

Budesonide and Formoterol Fumarate MDI 160/9.6 μg is included in this study to evaluate dose response by comparing to BFF MDI 320/9.6 μg. All doses represent the sum of 2 actuations. …

Efficacy and safety of budesonide/formoterol (Symbicort) Turbuhaler as Single Therapy in patients with mild-moderate asthma. Comparison with Symbicort Turbuhaler and PulmicortTurbuhaler …